Related Experiment Videos
Ras oncogene expression as a prognostic indicator in rectal adenocarcinoma
F Michelassi1, L E Vannucci, A Montag
1Department of Surgery, University of Chicago, Illinois.
The Journal of Surgical Research
|July 1, 1988
Summary
High levels of ras oncogene protein product (p21) in rectal adenocarcinoma correlate with a worse prognosis and increased distant metastases. Measuring p21 may help identify high-risk patients for better treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Ras oncogene expression is being investigated for its role in cancer progression.
- Prognostic indicators are crucial for tailoring treatment in rectal adenocarcinoma.
Purpose of the Study:
- To evaluate ras oncogene protein product (p21) levels as a prognostic indicator in rectal adenocarcinoma.
- To determine if p21 expression correlates with patient survival and disease recurrence.
Main Methods:
- Analyzed 149 rectal adenocarcinoma specimens (Dukes' B and C) from 1965-1981.
- Measured p21 protein levels using semiquantitative immunohistochemical assay with RAP-5 monoclonal antibody.
- Correlated p21 titers with 5-year survival, distant metastases, and Dukes' stage.
Main Results:
- High p21 titers (≥1:40,000) were associated with significantly worse 5-year survival (43.9% vs. 64.3%, P<0.02).
- Tumors with high p21 levels showed a higher incidence of distant metastases (51.8% vs. 23.2%, P<0.001).
- High p21 expression correlated with more advanced Dukes' stage (53.7% Dukes' C vs. 35.7%, P<0.04) and was an independent prognostic factor.
Conclusions:
- Elevated ras oncogene protein product (p21) indicates more aggressive rectal adenocarcinoma.
- High p21 levels are linked to increased distant recurrences and poorer prognosis.
- p21 measurement could be clinically valuable for identifying high-risk rectal cancer patients.